depression
Conditions
Interventions
Cabergoline will be added to the medication which the patients have been already taking at the time of their study participation. Cabergoline will be administered at 0.25 mg/day at first, 0.5mg/day at
Sponsors
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed as having depression based on Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). 2) Patients whose score on Hamilton Depression Rating Scale (HAM-D) 21-item version is 15 points or more despite 6 weeks or more treatment with adequate dose of at least one SSRI (Paroxetine, Fluvoxamine, or Sertraline). 3) Patients who are able to give informed consent by their free will after understanding the content of this study.
Exclusion criteria
Exclusion criteria: 1) Concomitant severe physical diseases 2) Pregnant women 3) Marked suicidal ideation as indexed by the three points or more on the "suicide" item of HAM-D 4) Comorbid other psychiatric disorders 5) Cardiac abnormalities assessed with ECG and echocardiography (only for Cabergoline group) 6) Patients who can result in serious outcomes by sleepiness including those who drive a car (for Pramipexole and Ropinirole groups)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Hamilton Depression Rating Scale (HAM-D) 2. Montgomery Asberg Depression Rating Scale (MADRS) 3. Clinical Global Impression (CGI) | — |
Countries
Japan
Outcome results
None listed